Redcare Pharmacy N.V. reported preliminary third-quarter sales figures showing significant growth across both prescription and non-prescription segments, with total sales increasing 25.2% to EUR 719 million compared to EUR 575 million in the same period last year. The company confirmed its full-year guidance across all elements, signaling confidence in sustained performance through the remainder of 2025.
The substantial growth in German prescription medication sales, which surged 82.1% to EUR 126 million in the third quarter, represents a critical development in the European healthcare landscape. This acceleration in digital pharmacy adoption reflects broader industry trends toward convenient healthcare access and suggests potential long-term shifts in how consumers obtain prescription medications. The company's performance indicates that e-pharmacies are gaining substantial market share from traditional brick-and-mortar pharmacies, particularly in Germany where regulatory changes have facilitated online prescription fulfillment.
Both the DACH and International segments demonstrated robust growth, with each achieving over 25% fully organic sales increases. The DACH segment, comprising Germany, Austria and Switzerland, saw sales rise to EUR 587 million, while the International segment covering Belgium, Italy, France and the Netherlands grew to EUR 132 million. This balanced growth across geographic markets suggests the company's business model is scalable and adaptable to different European healthcare systems.
Customer metrics showed continued positive trends, with active customers increasing to 13.7 million and the net promoter score improving significantly to well over 70, compared to 64 in the first half of the year. This high customer satisfaction level, combined with the substantial customer base, positions Redcare Pharmacy as a dominant player in the European e-pharmacy sector. The company's full interim report for the third quarter of 2025 will be released on October 29, 2025, available through their investor relations portal at https://www.redcare-pharmacy.com.
CEO Olaf Heinrich emphasized that growth remains profitable and cash generative, with Q3 EBITDA lifting the year-to-date margin already to the full-year guidance range of 2 to 2.5%. The company expects to achieve at least EUR 500 million in prescription medication sales for the full year, supported by accelerated Rx growth in Germany and the customary seasonal uplift in order volumes during the final quarter. Management confirmed that financial steering remains fully stable throughout the current transition period, with continuity ensured until the appointment of a new CFO.
The sustained growth trajectory has important implications for healthcare consumers, investors, and the broader pharmaceutical industry. For consumers, the expansion of reliable digital pharmacy options provides greater convenience, potentially lower costs, and improved access to medications. For investors, the consistent performance and guidance confirmation suggest stability in a sector that has experienced significant volatility. The pharmaceutical industry must adapt to this digital transformation, as traditional distribution models face increasing competition from efficient online platforms.
Year-to-date figures further underscore the company's strong performance, with total sales reaching EUR 2.15 billion, representing a 27% increase compared to the same period last year. Non-prescription sales grew 18% to EUR 1.4 billion year-to-date, while prescription sales in Germany showed remarkable growth of 122% to EUR 348 million. These figures indicate that Redcare Pharmacy is successfully executing its growth strategy while maintaining operational efficiency and customer satisfaction.
